ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of...